SCHEMBL29135401

SCHEMBL29135401

CCCCn1cc([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]c1=O

nearest known ligand 0.43

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TK2 O00142 7/20 0.43
CYP1A2 P05177 3/20 0.43
CYP2C19 P33261 3/20 0.43
CYP2C9 P11712 2/20 0.43
KMT2A Q03164 2/20 0.43
GAA P10253 1/20 0.43
MEN1 O00255 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
PYGM P11217 3/20 0.42
TK1 P04183 1/20 0.39
MAPT P10636 1/20 0.38
SLC5A2 P31639 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28358456 0.95 CYP1A2 (0.49) TK2CYP1A2CYP2C19CYP2C9KMT2A
SCHEMBL17210982 0.93 PYGM (0.44) TK2PYGMTK1SLC5A2
SCHEMBL15798586 0.93 PYGM (0.44) TK2PYGMTK1SLC5A2
SCHEMBL15810682 0.93 PYGM (0.44) TK2PYGMTK1SLC5A2
SCHEMBL18870659 0.93 PYGM (0.44) TK2PYGMTK1SLC5A2
SCHEMBL19007490 0.93 PYGM (0.44) TK2PYGMTK1SLC5A2
SCHEMBL12223731 0.92 CYP1A2 (0.43) TK2CYP1A2CYP2C19CYP2C9KMT2A
SCHEMBL12667540 0.92 CYP1A2 (0.43) TK2CYP1A2CYP2C19CYP2C9KMT2A
SCHEMBL12667528 0.88 PYGM (0.42) TK2PYGMSLC5A2
SCHEMBL12245097 0.88 PYGM (0.42) TK2PYGMSLC5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4569112-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING AT ALTERNATIVE SPLICE SITES Remix Therapeutics Inc. (US) 2025-06-18 EP disclosed
WO-2024035952-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING AT ALTERNATIVE SPLICE SITES REMIX THERAPEUTICS INC. (US) 2024-02-15 WO disclosed
CN-117355329-A VLP enterovirus vaccine 摩登纳特斯有限公司 2024-01-05 CN disclosed